YAG
JUNS

Yorkville Advisors Global’s Jupiter Neurosciences JUNS Stock Holding History

Yorkville Advisors Global’s Portfolio JUNS Stock Details JUNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,720
Closed -$48.5K – 52
2026
Q1 		$48.5K Sell
1,720
-39
-2% -$1.8K 0.03% 37
2025
Q4 		$135K Buy
+1,759
New +$175K 0.08% 22

Other funds holding JUNS

VC
Vestor Capital Chicago, Illinois $1.59B AUM 51.04% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Yorkville Advisors Global's JUNS Position: Q2 2026 in Review

Yorkville Advisors Global sold out of Jupiter Neurosciences (JUNS) in Q2 2026, closing a stake of 1,720 shares — an estimated $48.5K sold.

Yorkville Advisors Global first reported a position in JUNS in Q4 2025 and held it in 2 quarters. The position peaked at $135K in Q4 2025. 13 funds tracked by Wall St. Rank hold JUNS as of Q2 2026.

  • Yorkville Advisors Global reported no remaining Jupiter Neurosciences position as of Q2 2026 after selling out during the quarter.
  • Yorkville Advisors Global sold 1,720 Jupiter Neurosciences shares in Q2 2026, an estimated $48.5K.
  • Yorkville Advisors Global first reported a position in Jupiter Neurosciences in Q4 2025 and held it in 2 quarters.
  • Yorkville Advisors Global's Jupiter Neurosciences position peaked at $135K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q2 2026.

Based on Yorkville Advisors Global's 13F filing for Q2 2026, filed 6 Aug 2026.